kwic
clinical
clinical
right
off
ON
215
1
100
500
strict
ELIZA cgi-bash version rev. 1.90
- Medical English LInking keywords finder for the PubMed Zipped Archive (ELIZA) -
return
kwic search for clinical out of >500 occurrences
554339 occurrences (No.20 in the rank) during 5 years in the PubMed. [no cache] 500 found
--- ABSTRACT ---
--- ABSTRACT END ---
[frequency of next (right) word to clinical]
554339 occurrences (No.20 in the rank) during 5 years in the PubMed. [no cache] 500 found
| 215) This review will cover the clinical data regarding these emergent therapies that include new generation of proteasome inhibitors (carfilzomib, ixazomib, oprozomib, and marizomib), immunomodulatory drugs (pomalidomide), monoclonal antibodies (elotuzumab and daratumumab), signal transduction modulator (perifosine), and histone deacetylase inhibitors (vorinostat and panobinostat). |
| PMID:23934133 DOI:10.1097/COC.0b013e3182a4676b |
| 2015 American journal of clinical oncology |
| * Emerging therapies in multiple myeloma. |
| - The treatment of multiple myeloma has evolved significantly over the past 2 decades due to the use of high-dose chemotherapy and autologous stem cell transplantation, and the subsequent introduction of the immunomodulatory agents (thalidomide and lenalidomide) and the proteasome inhibitor (bortezomib). The median overall survival of multiple myeloma patients has increased significantly with patients younger than age 50 years experiencing a 10-year survival rate of around 40%. However, despite the increased effectiveness of the first-line agents, the majority of patients will eventually relapse and become drug resistant. Promising novel therapies have recently emerged and are being used to treat relapsed and refractory patients. This review will cover the clinical data regarding these emergent therapies that include new generation of proteasome inhibitors (carfilzomib, ixazomib, oprozomib, and marizomib), immunomodulatory drugs (pomalidomide), monoclonal antibodies (elotuzumab and daratumumab), signal transduction modulator (perifosine), and histone deacetylase inhibitors (vorinostat and panobinostat). |
[
right
kwic]
(1)36  and |
(17)5 application |
(33)3 attachment |
(49)2 grading |
| (2)26 practice |
(18)5 data |
(34)3 course, |
(50)2 interventions |
| (3)22 trials |
(19)5 efficacy |
(35)3 examination, |
(51)2 literature |
| (4)19 trial |
(20)5 features |
(36)3 experience |
(52)2 measures |
| (5)14 research |
(21)5 outcome |
(37)3 information |
(53)2 nurse |
| (6)14 studies |
(22)5 picture |
(38)3 manifestations |
(54)2 observations |
| (7)10 use |
(23)5 relevance |
(39)3 significance |
(55)2 point |
| (8)8 parameters |
(24)5 symptoms |
(40)3 variables |
(56)2 practice, |
| (9)8 settings |
(25)5 translation |
(41)2 benefits |
(57)2 presentation, |
| (10)8 signs |
(26)5 trials, |
(42)2 cases |
(58)2 process |
| (11)8 study |
(27)5 utility |
(43)2 conditions |
(59)2 results |
| (12)7 examination |
(28)4 characteristics |
(44)2 context |
(60)2 sample, |
| (13)7 implications |
(29)4 evaluation |
(45)2 decision-making |
(61)2 situation |
| (14)7 presentation |
(30)4 management |
(46)2 decisions |
(62)2 situations, |
| (15)6 applications |
(31)4 outcomes |
(47)2 diagnosis |
(63)2 success |
| (16)6 course |
(32)4 signs, |
(48)2 findings |
(64)2 tooth |
add keyword
--- WordNet output for clinical ---